Glenmark bags FDA approval for new generic

Glenmark Pharmaceuticals receives ANDA approval for Frovatriptan Succinate Tablets, 2.5 mg

id-10039602-1

Glenmark's drug is the therapeutic equivalent to the Frova Tablets, 2.5 mg, of Endo Pharmaceuticals

Glenmark Pharmaceuticals USA (Glenmark) has been granted final approval by the United States Food and Drug Administration (US FDA) for Frovatriptan Succinate Tablets, 2.5 mg, the therapeutic equivalent to the reference listed drug product, Frova Tablets, 2.5 mg, of Endo Pharmaceuticals.

According to IMS Health sales data for the 12 month period ending January 2016, the Frova Market achieved annual sales of approximately $87.8 million.

Glenmark's current portfolio consists of 108 products authorized for distribution in the US marketplace and 61 ANDA's pending approval with the FDA.

 

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X